Skye Bioscience Stock News

• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg) San Diego, Californ

San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid

Skye Bioscience Inc (OTCQB:SKYE) has entered into an agreement with Lexitas Pharma Services Inc, a full-service ophthalmic-focused contract research organization (CRO) for its planned Phase 2a study o

Skye Bioscience Inc (OTCQB:SKYE) said it has received a positive recommendation following a pre-specified data review by the safety review committee (SRC) based on dosing of the first cohort of eight

Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE Phase 2 clinical trial planned to start in H1 2023San Diego, California, December 20, 2022 -- InvestorsHub NewsWire -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, today announced that the U.S. Food and Drug Administration ("FDA") has given the okay to proceed for the Investi...

Skye Bioscience Inc (OTCQB:SKYE) said the US Food and Drug Administration (FDA) has authorized it to proceed with the Investigational New Drug (IND) application for SBI-100 Ophthalmic Emulsion (OE),�

 Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion San Diego, California, December 16, 2022 -- InvestorsHub NewsWire -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of SBI-100 Ophthalmic Emulsion ("OE") in the first cohort of healthy participants in the single ascen...

Skye Bioscience Inc (OTCQB:SKYE) said it has completed dosing of SBI-100 Ophthalmic Emulsion (OE) in the first cohort of healthy participants in the single ascending dose (SAD) part of its Phase 1 stu

Skye Bioscience Inc (OTCQB:SKYE) said it has hired Dr Chris Twitty as the company's first chief scientific officer (CSO).  With over 25 years of life science research and drug development experience,

San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid de

Skye Bioscience Inc (OTCQB:SKYE) said it has submitted an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for its SBI-100 Ophthalmic Emulsion (SBI-100 OE), whic

Skye Bioscience Inc (OTCQB:SKYE) said it has started screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion (SBI-100 OE), a proprietary, synthetic cannabinoid derivative intend

Skye Bioscience Inc (OTCQB:SKYE) announced that it has concluded the merger with Emerald Health Therapeutics after both companies' shareholders voted in favor and the Supreme Court of British Columbia

Skye Bioscience Inc (OTCQB:SKYE) said it has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (SBI-100 OE) for Skye's phase one clinical tr

Skye Bioscience Inc (OTCQB:SKYE) has announced that the shareholders of Emerald Health Therapeutics Inc (CSE:EMH, OTCQX:EMHTF) have approved the proposed plan of arrangement which will result in the i